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journal.publications.chestneBACKGROUND: This study assessed if bronchiectasis (BR) and rheumatoid arthritis (RA),
when manifesting as an overlap syndrome (BROS), were associated with worse outcomes
than other BR etiologies applying the Bronchiectasis Severity Index (BSI).
METHODS: Data were collected from the BSI databases of 1,716 adult patients with BR across
six centers: Edinburgh, United Kingdom (608 patients); Dundee, United Kingdom (n ¼ 286);
Leuven, Belgium (n ¼ 253); Monza, Italy (n ¼ 201); Galway, Ireland (n ¼ 242); and
Newcastle, United Kingdom (n ¼ 126). Patients were categorized as having BROS (those with
RA and BR without interstitial lung disease), idiopathic BR, bronchiectasis-COPD
overlap syndrome (BCOS), and “other” BR etiologies. Mortality rates, hospitalization, and
exacerbation frequency were recorded.
RESULTS: A total of 147 patients with BROS (8.5% of the cohort) were identiﬁed. There was a
statistically signiﬁcant relationship between BROS and mortality, although this relationship
was not associated with higher rates of BR exacerbations or BR-related hospitalizations. The
mortality rate over a mean of 48 months was 9.3% for idiopathic BR, 8.6% in patients with
other causes of BR, 18% for RA, and 28.5% for BCOS. Mortality was statistically higher in
patients with BROS and BCOS compared with those with all other etiologies. The BSI scores
were statistically but not clinically signiﬁcantly higher in those with BROS compared with
those with idiopathic BR (BSI mean, 7.7 vs 7.1, respectively; P < .05). Patients with BCOS
had signiﬁcantly higher BSI scores (mean, 10.4), Pseudomonas aeruginosa colonization rates
(24%), and previous hospitalization rates (58%).
CONCLUSIONS: Both the BROS and BCOS groups have an excess of mortality. The
mechanisms for this ﬁnding may be complex, but these data emphasize that these subgroups
require additional study to understand this excess mortality.
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Non-cystic ﬁbrosis bronchiectasis (hereafter referred to
as bronchiectasis [BR]) is a chronic respiratory disorder
characterized by recurrent cough, sputum production,
and respiratory infections.1 Pathologically, patients have
abnormally dilated bronchi leading to impairment of
host defenses, chronic infection with bacteria, and
airways inﬂammation.2,3
Rheumatoid arthritis (RA) is a common autoimmune
disease associated with many extra-articular features. RA
has numerous pulmonary complications, including
interstitial lung diseases, which may lead to “traction” BR;
the association between RA and BR without interstitial
lung disease (hereafter referred to as BROS) is well
recognized. Studies note a signiﬁcantly higher prevalence
of symptomatic BR in patients with RA (approximately
3%) compared with 0.03% in the general population.4
Supporting this ﬁnding are high-resolution CT scanning
studies consistently reporting a high prevalence (up to
30%) of radiologic evidence of BR in RA populations.5,6
Earlier single-center studies have suggested that
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We identiﬁed that when compared with patients with
RA alone, patients with BROS have higher indices
of RA activity (eg, 28-item Disease Activity Scores),
demonstrating worse RA and higher levels of RA
seropositivity.7
The goal of the present study, therefore, was to
determine if BROS was associated with poorer outcomes
compared with BR without RA. Deﬁning the clinical
severity of BR had been problematic until scoring
indices such as the Bronchiectasis Severity Index (BSI)
became available.8 We sought to assess the mortality,
frequency of exacerbations, hospital admissions,
reported health-related quality of life, and BSI scores in
an international cohort comparing BROS vs BR without
RA. Idiopathic BR was used as a benchmark because of
its prevalence and a perception that this etiologic group
may have better outcomes.1 Because BR and COPD
overlap syndrome (BCOS) has been linked to excess
mortality, this second group was used as an additional
reference group.9Patients and Methods
Multicenter Assessment of BR Severity
Six independent cohorts of patients were collected from specialist BR
services in Edinburgh, Dundee, and Newcastle (United Kingdom),
Leuven (Belgium), Monza (Italy), and Galway (Ireland); the average
follow-up was 4 years.8,10 Consecutive adult patients were enrolled
on the basis of a diagnosis of BR made by using high-resolution CTscans and a clinical history consistent with BR.1 Patients were
excluded if they had active malignancy at enrollment, cystic ﬁbrosis,
active mycobacterial disease (including active nontuberculous
mycobacteria), HIV, or a primary diagnosis of pulmonary ﬁbrosis/
sarcoidosis with secondary traction BR. Patients with BCOS were not
included within the Edinburgh cohort because of their cohort
building protocol. Patient cohort recruitment was approved at each
individual center; by the South East Scotland Research Ethics
Committee, Research ethics service multicenter ethics, IRAS 12324
and by NRES, UK 12/NE/0298, CA 128 Clinical research committee,
Galway.8,10Etiologic Categorization
The underlying etiology of BR was determined following testing
recommended by the British Thoracic Society guidelines.1 This
testing includes serologic and clinical assessments for RA.
BROS required a diagnosis of both BR, as noted earlier, and RA,
deﬁned according to the 2010 American College of Rheumatology
and the European League Against Rheumatism RA criteria11 and
local prevailing clinical guidelines. Patients were grouped into the
BROS category irrespective of which of the two conditions preceded
the other.
Patients were pragmatically categorized as having BCOS based on
evidence of airﬂow obstruction and smoking > 20 pack-years. The
presence of emphysema on CT scanning was not a prerequisite.
Postinfectious causes were attributed when a clear history of BR
following an acute infectious episode was reported.1 Inﬂammatory
bowel disease and allergic bronchopulmonary aspergillosis-associated
etiologic categories were applied when a clear history and/or
appropriate serologic and history were reported, respectively.
Idiopathic was attributed as a diagnostic grouping in the absence of
any recognized etiology. “Other” BR was a grouping of categories[ 1 5 1 # 6 CHES T J U N E 2 0 1 7 ]
that included all remaining etiologic groups (eg, immunodeﬁciency-
associated BR, including those taking immunoglobulin replacement,
those with ciliary dyskinesia).
Clinical Assessments
At the time of clinical assessment, all patients were clinically stable
with no antibiotic use in the preceding 4 weeks. All patients
underwent spirometry (FEV1 and FVC) according to European
Respiratory Society guidelines, with the highest of three technically
satisfactory measurements recorded.
Radiologic Severity
Radiologic severity of BR was assessed by using a modiﬁed Reiff score,
which has been used previously in BR studies.8,12,13 The score assesses
the number of lobes involved (with the lingula considered to be a
separate lobe) and the degree of bronchial dilatation (tubular, 1;
varicose, 2; and cystic, 3) with a maximum score of 18 and
minimum score of 1. There was no minimum Reiff score for
patients to be entered into the cohorts.
Bacteriology
As previously described, all bacteriologic studies were performed by
using local culture protocols on spontaneous early morning sputum
samples.3 The deﬁnition of chronic persistent infection was the
isolation of potentially pathogenic bacteria in sputum culture on $ 2
occasions, at least 3 months apart in a 1-year period.13-15 The
microorganism grown most frequently over the study period was
classiﬁed as the predominant pathogen. The clinical standards were
sputum sampling at six monthly or more frequent intervals at clinic
reviews.
BSI Scores
As previously described, BSI scores were grouped as follows: scores of
0 to 4 represent mild BR; scores of 5 to 8 indicate moderate BR; and
scores > 8 represent severe BR.8journal.publications.chestnet.orgEnd Points
At the end of the follow-up periods, mortality was determined through
notes review and examining national death records. Survival status was
conﬁrmed for 100% of participants, although exact date of death was
not available for all deceased patients.
Exacerbations were deﬁned according to the British Thoracic Society
description as an acute deterioration with worsening and/or systemic
upset.1 Severe exacerbations were deﬁned as those needing
hospitalization. The frequency of exacerbations requiring antibiotic
treatment was determined from clinic records and patient histories,
and this information was veriﬁed against primary care prescription
records.
Statistical Analysis
Normally distributed data are presented as mean  SD, and
nonnormally distributed data are presented as medians with
interquartile ranges. The c2 test and Mann-Whitney U test were
used for comparison of categorical and numerical data, respectively.
For comparisons of > 2 groups, one-way ANOVA or the
Kruskal-Wallis test was used as appropriate. For all analyses, a
P value < .05 was considered statistically signiﬁcant. Independent
relationships between BROS and BCOS with mortality were
assessed by using multivariable logistic regression, adjusting for the
BSI. Data are presented as ORs with 95% CIs. Kaplan-Meier
survival curves and Cox proportional hazards regression were
performed for survival.
The discrimination of the BSI for predicting mortality in BROS was
assessed by using the area under the receiver-operating characteristic
curve. Sensitivity analyses were performed to determine if outcomes
were different across all three BSI categories (mild, moderate, and
severe). In addition, we applied calibration analysis, an analysis to
determine whether scoring systems perform similarly in a different
population compared with the baseline population. As a sensitivity
analysis to determine the validity of pooling cohorts, random effects
meta-analysis was used. Data were pooled by using the
Mantel-Haenszel method, and heterogeneity was assessed by using
Higgins I2 test and Cochran’s Q test.Results
Multicenter Assessment
Data were collected from 1,716 adult patients with BR
across six centers in Western Europe. The data are
displayed in Figure 1 and Table 1. The patients’ median
age was 65 years, with a female predominance, and
the most common etiologic groups were idiopathic
and postinfectious, suggesting these were broadly
representative of BR cohorts previously reported.1
Overall, BROS was present in 8.5% of the cohort,
whereas BCOS was present in 12% of the cohorts that
included BCOS during cohort building. The mean
exacerbation frequency was > 2 exacerbations per
year, and all cohorts reported a history of
hospitalization in at least 20% of patients. Chronic
Pseudomonas aeruginosa infection was present in a
mean of 13% of patients overall. The mean BSI scores
for each center ranged from 6 to 9. Previous data haveshown that this ﬁnding is consistent with patients
with moderate to severe BR.8 The center with the
highest hospital admission rate (Newcastle) also had
the highest observed mean BSI score (ie, 9.6).
Comparison Between BROS and Non-RA Patients
With Bronchiectasis
The comparisons between BROS and other groups are
shown in Table 2. In general, patients with BROS were
similar in terms of age and sex distribution except
compared with the BCOS group, who were signiﬁcantly
older and signiﬁcantly more likely to be male. The BSI
scores were statistically signiﬁcantly higher in the BROS
group compared with the idiopathic group and other BR
groups, although all remained within the moderate
severity category of the BSI (scores, 5-8). Radiologic
burden of disease was not signiﬁcantly different across
all groupings, with three lobes involved as an average.
Notably, both the BCOS group and the BROS group had1249
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Figure 1 – CONSORT 2010 ﬂow diagram.statistically signiﬁcantly more exacerbations and
previous BR-related hospitalizations than the idiopathic
BR group (BROS mean number of exacerbations 2.4 and
26.1% hospitalization rate, BCOS 2.7 exacerbations and
58.4% vs BR 1.8 and 25.1%, P < .05; Table 2). As
expected, the mean FEV1 % predicted was both
statistically and clinically signiﬁcantly lower in the
BCOS group, in part reﬂecting the need for airﬂow
obstruction to be present in this diagnostic grouping.
Outcomes in BROS
The mortality rate over a mean of 48 months of follow-
up was 8.6% in patients with other causes of BR, 9.3% in
idiopathic BR, 18% for RA, and 28.5% for BCOS. There
was no signiﬁcant difference in follow-up duration
among any of the four cohorts to explain the differences
in mortality (mean, 46, 48, 47, and 47 months,
respectively) (Fig 2).
Using logistic regression, there was a signiﬁcant
univariate association between RA and increased
mortality (OR, 1.82 [95% CI, 1.15-2.89]; P ¼ .01).
This scenario persisted after multivariable adjustment
for BSI (OR, 1.83 [95% CI, 1.11-3.02]; P ¼ .01). The
relationship was greater in the fully adjusted model
(including etiology, all BSI individual components) (OR,
2.03 [95% CI, 1.19-3.44]; P ¼ .009). COPD was also
independently associated with worse outcome in all1250 Original Researchmodels adjusted (OR, 2.47 [95% CI, 1.55-3.92] in the
fully adjusted model). No other etiologies were
independently associated with outcome (Hosmer-
Lemeshow goodness-of-ﬁt test, P ¼ .7 [indicating
excellent model ﬁt]).
There was, however, no signiﬁcant relationship between
RA and hospital admission risk during follow-up (OR,
0.84 [95% CI, 0.42-1.67]; P ¼ .6). There was no
signiﬁcant relationship between RA and more frequent
exacerbations according to multiple linear regression
(adjusted for BSI: estimate, 0.15; SE, 0.18; P ¼ .5).
The results were conﬁrmed by using Cox proportional
hazards regression. The hazard ratio for RA and
mortality was 1.88 (95% CI, 1.11-3.21; P ¼ .01). The
Kaplan-Meier survival curve is shown both for BCOS
and BROS in Figure 2.
Prediction
Despite clear variations in mortality rates associated
with different etiologies, the BSI showed good
discrimination in patients with BROS. It yielded an area
under the receiver-operating characteristic curve of 0.77
(95% CI, 0.67-0.87; P < .0001).
We also applied a calibration analysis to determine
whether the BSI scoring systems perform similarly well
in a different population, such as BROS compared with
the overall BR population. RA was associated with an
increased mortality risk across all BSI subgroups: OR of
2.57 (95% CI, 0.48-13.9) in low-risk patients, 2.1
(95% CI, 0.8-5.5) in intermediate-risk patients, and 1.64
(95% CI, 0.83-3.3) in high-risk patients (interaction test,
P ¼ .8). This analysis indicated that RA increases the
risk across the full spectrum of BR severity categories
and should be considered additive to the BSI.
Validation of the Pooled Analysis
Using random effects meta-analysis of the six cohorts,
RA was associated with increased mortality (OR, 1.70
[95% CI, 1.07-2.70]; P ¼ .02). Importantly, there was no
heterogeneity in this relationship across all six studies
(I2 ¼ 0%; Cochran Q test, P ¼ .6).
Discussion
BR and RA are undoubtedly linked and may present in
patients in a variety of temporal and causal ways.4,5,7 BR
seems to predispose to later RA, and “BRRA” could be
used to deﬁne this syndrome.5 Patients with RA are
known to develop BR as their articular disease progresses
and could be described as “RABR.” A third group could[ 1 5 1 # 6 CHES T J U N E 2 0 1 7 ]
TABLE 1 ] Details of the European BR Cohorts
Variable
Leuven
(Belgium)
Galway
(Ireland)
Monza
(Italy)
Edinburgh
(UK)
Newcastle
(UK)
Dundee
(UK)
Total 253 (100) 242 (100) 201 (100) 608 (100) 126 (100) 286 (100)
Demographic
Age, median (IQR), y 68 (56-78) 63 (53-71) 68 (59-73) 67 (58-75) 61 (54-69) 68 (61-75)
Male sex 127 (50) 76 (31) 80 (39) 243 (40) 51 (41) 115 (42)
Etiologya
Idiopathic 78 (31) 98 (40) 79 (39) 261 (42) 52 (41) 124 (43)
Postinfective 50 (19) 41 (17) 51 (25) 207 (34) 28 (22) 51 (17)
ABPA 15 (6) 5 (2) 4 (2) 49 (8) 8 (6) 31 (11)
BCOS 42 (17) 26 (11) 49 (24) 0b 15 (12) 7 (2)
Immunodeﬁciency 18 (7) 13 (5) 9 (4) 6 (1) 14 (11) 16 (6)
BROS 25 (10) 55 (23) 2 (1) 44 (7) 11 (9) 10 (4)
IBD 5 (2) 4 (2) 6 (3) 14 (2) 2 (1) 8 (3)
Severity markers
Exacerbations/y 1.8  2.0 3.2  1.3 1.9  1.9 1.7  2.0 3.4  1.7 2.1  1.8
Previous hospital
admissions
67 (26) 63 (26) 56 (27) 133 (21) 74 (58) 66 (23)
% Pseudomonas
aeruginosa
20 (8) 35 (14) 39 (19) 70 (12) 13 (10) 37 (14)
Lobes involved on
CT scanning
2.9  1.3 2.7  1.3 2.8  1.4 3.0  1.6 2.8  1.4 3.2  1.6
Mean FEV1 % predicted 70.1  27 77.5  24 71.7  35 72.6  25 64.0  27 72.1  26
Mean BSI score 6.7  4.8 7.2  4.4 7.2  4.5 7.3  4.8 9.6  4.9 7.1  4.5
Data are presented as No. (%) or mean  SD unless otherwise indicated. ABPA ¼ allergic bronchopulmonary aspergillosis; BCOS ¼ bronchiectasis and
COPD overlap syndrome; BR ¼ bronchiectasis; BROS ¼ bronchiectasis-rheumatoid arthritis overlap syndrome; BSI ¼ bronchiectasis severity index; IBD ¼
inﬂammatory bowel disease; IQR ¼ interquartile range.
aLess frequent etiologies are not shown.
bPatients with BCOS were excluded from this cohort.include those who coincidentally have both conditions
without any causal relationship. Reﬂecting concerns over
recall bias and inaccuracy in pinpointing the onset of a
particular condition (in contrast to the time when it was
diagnosed), we have opted to use the terminology BROS
to encompass all three of these scenarios.TABLE 2 ] Comparison Between BROS and Non-RA Patient
Variable BROS
Age, median (IQR), y 69 (60-76)a
Sex 34.3% malea
Exacerbations/y 2.4  1.9
Previous hospital admissions 26.1%a
Pseudomonas aeruginosa infection 14.3%a
Lobes involved on CT scanning 3.0  1.5
Mean FEV1 % predicted 76%  25a
Mean BSI score 7.7  4.6a
Data are presented as mean  SD unless otherwise indicated. See Table 1 leg
aP < .05 compared with BCOS.
bP < .05 compared with BROS.
journal.publications.chestnet.orgTo our knowledge, this study is the ﬁrst multicenter
international study to apply the recently validated BSI
to deﬁne the severity of BR in patients with comorbid RA.
We report data in almost 150 patients with BROS from a
1,716-patient cohort followed up over an average of 4
years with BR in the largest and only multicenter study tos With BR
Idiopathic BR BCOS Other BR
67 (58-74)a 73 (65-78)b 64 (55-72)a,b
38.2% malea 70.0% maleb 38.4% malea
1.8  1.9a,b 2.7  2.0 2.2  2.0
25.1%a 58.4%b 23.7%a
14.7%a 24.1%b 14%a
2.8  1.5 3.1  1.4 3.0  1.5
76%  25a 51%  22b 74%  25a
7.1  4.6a,b 10.4  4.5b 6.9  4.3a,b
end for expansion of abbreviations.
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Figure 2 – Kaplan-Meier survival curve is shownboth forBCOSandBROS.
BCOS¼ bronchiectasis andCOPDoverlap syndrome; BR¼ bronchiectasis;
BROS ¼ bronchiectasis-rheumatoid arthritis overlap syndrome.date to deﬁne the impact of RA in BR. We benchmarked
this group against a group increasingly recognized as
having poorer outcomes, namely those with BCOS, and
those often perceived to have more favorable outcomes,
namely “idiopathic” BR. We found, however, that
although there was a statistically signiﬁcantly higher BSI
score in the BROS group compared with the idiopathic
BR group (BSI mean, 7.7 vs. 7.1; P < .05), this outcome
was not likely to be clinically signiﬁcant because the mean
BSI scores were both within the moderate BSI category
(BSI score, 5-8).
Importantly however, the present study found that
BROS was signiﬁcantly associated with increased
mortality compared with idiopathic BR syndrome.
Indeed, mortality with BROS approached that seen
in BCOS.9,16 Using multiple modeling methods, we
showed that the mortality risk over 4 years was
increased by approximately 80% and, when adjusted
for all components of the BSI, that the OR reached
2.0, indicating a doubling of mortality risk. This effect
was replicated in survival analyses, conﬁrming that
BROS is associated with higher mortality.
Importantly, this outcome seems independent of
the rates of hospitalization, nonhospitalized
exacerbations, and spirometric and radiologic markers
of disease burden.
The co-existence of BR and RA has previously been
suggested to have major clinical signiﬁcance. In 1997, a
single-center UK study reported that patients with both
BR and RA (BROS) had greatly elevated standardized
mortality ratios 7.3 times higher than the general
population, 5 times that of patients with RA alone, and 2.4
times that of patients with BR over 5 years.17Our observed1252 Original Researchmortality rates herein were 18%, and the OR for mortality
was slightly less than that reported in the aforementioned
study. Careful review of this previous research suggests
potential case ascertainment bias with a more severe
BROS subgroup selected: only 32 patients with BROS
were identiﬁed from their RA cohort of 3,000 (1%). Their
reported prevalence rate was lower than we observed
(approximately 8%) and contrasts to more recent studies
suggesting prevalence rates ranging from 3% to
30% radiologically. Nevertheless, a single-center case-
control study of patients recruited from 1999 to 2002
reported an excess of mortality over an 11-year follow-up
period.18 The patients with BROS also had a poorer
prognosis in terms of survival after diagnosis of RA
(hazard ratio, 8.6 [95% CI, 1.5-48.2]; P ¼ .014) and from
birth (hazard ratio, 9.6 [95% CI, 1.1-81.7]; P ¼ .039).
Divergence in mortality rates was seen within the ﬁrst 5
years in this study. Collectively, these previous data and
our international multicenter observations support BROS
as a risk for poorer outcomes.
The reasons for this ﬁnding may be distinct to the
pulmonary disease component as suggested by the
similar rates of exacerbation and lung function seen
between BROS and idiopathic BR noted in the present
study. This effect may be more clearly observed in those
with milder BR as suggested by our sensitivity analysis.
It is possible that the treatments used for RA, which
include powerful immunosuppressant drugs, may affect
survival, but our study was not designed to deﬁne the
reasons for poorer outcomes. In this study, we did not
have funding to collect detailed information on the
management of RA and were therefore unable to assess
the role of this factor in the observed increased
mortality. Notably, however, in our previous research,
we found no signiﬁcantly different rates of disease-
modifying antirheumatic drug therapy between patients
with RA and BROS in an intensively characterized UK
cohort.19 We did, however, report greater rates of
autoantibody seropositivity, inﬂammatory markers, and
joint involvement, suggesting the BROS syndrome is
associated with greater immune activation and systemic
inﬂammation.7,19 This ﬁnding is noteworthy because RA
has been associated with an excess of cardiovascular
deaths and is now incorporated as an independent risk
factor in the cardiovascular QRISK2 scoring system.20
BR has also been recently linked with excessive
cardiovascular risk,21 and this link may be an
underpinning mechanism for excess mortality in BROS,
with additive cardiovascular risk driven by each
proinﬂammatory comorbidity. This theory requires[ 1 5 1 # 6 CHES T J U N E 2 0 1 7 ]
further mechanistic research that was not possible in the
present study because only limited data collection was
possible.
We also showed that the BSI scoring system still predicts
poorer mortality outcomes in those with BROS and that
the effects are seen across the range of BSI categories. RA
is certainly an additive and independent predictor of
severity/death, and etiology may need incorporation in
future risk stratiﬁcation systems. To benchmark the
outcomes in BROS, a previously described BR etiology
associated with poor outcomes was used.
We showed that BCOS has an elevated mortality risk
(28% risk of death over 4 years), which is much higher
than that reported in the selected population recruited
into the Towards a Revolution in COPD Health
(TORCH) study (patients who had an average FEV1 of
approximately 60% [15% mortality over 3 years]).22 The
mortality rates in the BCOS population were high and in
the order of those reported in patients with Global
Initiative for Chronic Obstructive Lung Disease stage II/
III COPD (or those within body mass index, airﬂow
obstruction, dyspnea, exercise capacity [BODE] index
quartile 3) in the BODE index cohort and in other
studies.23,24 We extend the ﬁndings of Gatheral et al25
showing that BCOS is associated with a high hospital
admission rate (58% in this series) and that persistent
P aeruginosa infection is common in BCOS
(24% herein). In contrast to an article from the United
Kingdom, which did not report an excess of mortality in
BCOS compared with COPD alone,25 we conﬁrm
research from other investigators9,16,26 that BCOS is
associated with excess mortality compared with other
BR etiologies. These differences may be explained by the
comparator groups; Gatheral et al25 compared patients
with BCOS vs patients with relatively severe COPD,
whereas in the other studies and our present study, the
comparator group has been BR, often including those
with mild disease.26 Our deﬁnition of BCOS may have
incorrectly categorized patients as having idiopathic BR
who previously smoked as BCOS. Nevertheless, our
pragmatic deﬁnition seems to have conﬁrmed the
ﬁndings reported from single centers.9,16,26 Consensus
exists regarding the need to better deﬁne BR phenotypes
and predictors of mortality.27,28
One area to focus on is BCOS, a syndrome that is clearly
adversely prognostic yet difﬁcult to deﬁne precisely,
where the mechanisms leading to adverse outcomes are
imprecise (as reviewed by Hurst et al28). BROS clearly is
another area also requiring better understanding. Wejournal.publications.chestnet.orgdid not have prescription records of immunosuppressive
therapies to target RA in this patient population; such
therapies may inﬂuence both infection rates and possibly
mortality in the setting of BROS. These data will be
prospectively collected in UK national and European
observational cohorts and should allow future
associations to be explored (www.bronch.ac.uk).29
Our study has inherent limitations in addition to those
relating to concomitant medications. We excluded
patients with active nontuberculous mycobacterial
disease and patients with known RA-related interstitial
lung disease. These factors may have contributed to the
differences in the BSI scores between groups. We cannot,
however, exclude the possibility of “missed” cases of
BROS being incorrectly classiﬁed as idiopathic BR in any
of the cohorts, although serologic testing for RA was
conducted in all cohorts. The pooling of data from
multiple centers may be regarded as a limitation because
there was some heterogeneity in the populations, such as
the exclusion of patients with BCOS from the Edinburgh
cohort (this choice reﬂected an a priori decision at that
recruiting center).8 Nevertheless, in our sensitivity
analysis, no signiﬁcant heterogeneitywas demonstrated in
the relationship between BROS and mortality, and we
therefore regard the robustness of this ﬁnding across
multiple centers as a strength and not as a weakness. We
did not assess RA serology repeatedly, only doing so at a
patient’s ﬁrst clinic review or when new symptoms
prompted a clinical suspicion of RA. It is therefore
possible that these patients with BR may have
inadvertently included some patients with subclinical or
early-stage RA who should have been placed in the BROS
category. Lastly, our mortality data did not compare
outcomes in BROS vs a cohort of patients with RA alone;
the recorded cause of death was also not included. These
data will be highly relevant to future studies.
Conclusions
In the largest cohort studied to date, both BROS and
BCOS were shown to be associated with poorer
outcomes, and they should be investigated further as a
priority in longitudinal and mechanistic studies to assess
drivers of mortality.28,29 The current data support the
premise that patients with BROS are at higher risk of
premature death, and a multidisciplinary approach
involving chest and rheumatology physicians is needed.
Patients with BROS with “mild” BR deﬁned
radiologically by extent or by using composite scoring
systems may need closer monitoring than those with
other etiologies causing BR.1253
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